Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway
Humoral immunity to factor VIII (FVIII) represents a significant challenge for the treatment of patients with hemophilia A. Current paradigms indicate that neutralizing antibodies against FVIII (inhibitors) occur through a classical CD4 T cell, germinal center (GC) dependent process. However, clinic...
Main Authors: | Seema R. Patel, Taran S. Lundgren, Wallace Hunter Baldwin, Courtney Cox, Ernest T. Parker, John F. Healey, Ryan P. Jajosky, Patricia E. Zerra, Cassandra D. Josephson, Christopher B. Doering, Sean R. Stowell, Shannon L. Meeks |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.880829/full |
Similar Items
-
Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity
by: Patricia E. Zerra, et al.
Published: (2022-07-01) -
Early IgE Production Is Linked with Extrafollicular B- and T-Cell Activation in Low-Dose Allergy Model
by: Dmitrii Borisovich Chudakov, et al.
Published: (2022-06-01) -
Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
by: Glaivy Batsuli, et al.
Published: (2023-08-01) -
Adenomatoid Odontogenic Tumor: Intraosseous Variant–A Case Series and Review of Literature
by: Lavina Taneja, et al.
Published: (2017-01-01) -
An Unusual Presentation of “Two-Thirds Tumor” in the Mandible – A Diagnostic Quandary with a Review of the Literature
by: Jayapriya T, et al.
Published: (2022-12-01)